


Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

Telephone: 858 587 9333

Fax: 858 587 6470



HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.8

Serial No. : 10/087,929

Applicant(s) : Clarence N. Ahlem, et al.

For : Blood Cell Deficiency Treatment Method


Attorney : Daryl D. Muenchau, Reg. No. 36,616

Date of Deposit : February 6, 2004

I hereby certify that the accompanying

Transmittal (in duplicate); Information Disclosure Statement (Form PTO-1449 – including reference copies); and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated above and are addressed to: Assistant Commissioner of Patents, Alexandria, VA 22313-1450.


Brenda J. Mannon-Freeman



PATENT
Docket No. 202.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/087,929
Filed : March 1, 2002
Title : Blood Cell Deficiency Treatment Method
Examiner : Sabiha N. Qazi
TC/A.U. : 1616

Docket No. : 202.8
Customer No. : 26551
Confirmation No. : 7989

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Assistant Commissioner of Patents
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references (76). A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: Feb 6, 2004

By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551



PATENT
Docket No. 202.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/087,929
Filed : March 1, 2002
Title : Blood Cell Deficiency Treatment Method
Examiner : Sabiha N. Qazi
TC/A.U. : 1616

Docket No. : 202.8
Customer No. : 26551
Confirmation No. : 7989

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Assistant Commissioner of Patents
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references (76). A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.


Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: Feb 6, 2004

By: Daryl D Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

FEB 09 2004

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,395,722	5/28/02	Gilat			
	6,667,299 B1	12/23/03	Ahlem et al.			

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	09/820,483	Ahlem et al.			
	10/087,929	Ahlem et al.			
	10/166,423	Labrie			6/11/99
	10/319,356	Ahlem, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	GB 2 057 448	4/1/81	United Kingdom				
	WO 97/13500	4/17/97	PCT				
	WO 97/17992	5/22/97	PCT				
	WO 97/48401	12/24/97	PCT				
	WO 00/56757	9/28/00	PCT				
	WO 01/30802	5/3/01	PCT				
	WO 01/42273	6/14/01	PCT				

EXAMINER
INITIAL


OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

Araghi-Niknam, et al, Cytokine dysregulation and increased oxidation is prevented by dehydroepiandrosterone in mice infected with murine leukemia retrovirus, *Proc. Soc. Exp. Biol. Med.* 216, pages 386-391 (1997)

EXAMINER


DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
	APPLICANT Ahlem, et al.	
	FILING DATE 3/1/02	GROUP 1616

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Araghi-Niknam, et al, Modulation of immune dysfunction during murine leukemia retrovirus infection of old mice by dehydroepiandrosterone sulfate (DHEAS), <i>Immunology</i> , 90, pages 344-349 (1997)
	Bebo, et al, Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, <i>J. Immunology</i> , 162, pp. 35-40, (1999)
	Henderson, et al, Dehydroepiandrosterone and 16.alpha.-bromoepiandrosterone: inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, <i>Carcinogenesis</i> , vol. 2, no. 7, pages 683-686 (1981)
	Hernandez-Pando, et al, The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> , 95, pages 234-241 (1998)
	Inserra, et al, Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, <i>Proc. Soc. Exp. Biol. Med.</i> , 218, pages 76-82 (1998)
	Kang, et al, Dehydroepiandrosterone and beta-endorphin enhance IL-12 gene expression, <i>Chemical Abstracts</i> , vol. 126, no. 9, 399-404 (1997)
	Manz, et al, Methyl 17.beta.-carboxyester derivatives of natural and synthetic glucocorticoids: correlation between receptor binding and inhibition of in vitro phytohaemagglutinin-induced lymphocyte blastogenesis, <i>J. Clin. Chem. Clin. Biochem</i> , 21, 69-75 (1983)
	Yang et al, Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> , Vol. 9, no 8, 747-754, 1993
	Zhang, et al, Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> , 96, 291-297 (1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
	APPLICANT Ahlem, et al.	
	FILING DATE 3/1/02	GROUP 1616

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2,531,441	11/28/50	Julian et al.			
	2,561,378	7/24/51	Julian et al.			
	2,566,336	9/4/51	Julian et al.			
	2,705,238	3/29/55	Julian et al.			
	3,001,988	9/26/61	Nysted			
	3,004,968	10/17/61	Jeger et al.			
	3,026,318	3/20/62	Hewett			
	3,080,360	3/5/63	Pappo			
	3,153,063	10/13/64	Ruggieri et al.			
	3,189,597	6/15/65	MacPhillamy et al.			
	4,263,290	4/21/81	Nedelec et al.			
	4,292,251	9/29/81	Overbeek			
	4,310,523	1/12/82	Neumann			
	4,329,296	5/11/82	Tax			
	4,330,539	5/18/82	Sleigh et al.			
	4,424,218	1/3/84	Deraedt et al.			
	4,602,008	7/22/86	Krsek			
	4,898,694	2/6/90	Schwartz et al.			
	4,956,355	9/11/90	Prendergast			
	5,001,119	3/19/91	Schwartz et al.			
	5,028,631	7/2/91	Schwartz et al.			
	5,077,284	12/31/91	Loria et al.			
	5,145,874	9/8/92	Johnson et al.			
	5,175,154	12/29/92	Schwartz et al.			
	5,206,008	4/27/93	Loria			
	5,372,996	12/13/94	Labrie			
	5,387,583	2/7/95	Loria			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	5,206,008	4/27/93	Loria			
	5,407,684	4/18/95	Loria et al.			
	5,424,463	6/3/95	Lardy			
	5,461,042	10/24/95	Loria			
	5,478,566	12/26/95	Loria			
	5,489,581	2/6/96	Daynes et al.			
	5,494,899	2/27/96	Kincade et al.			
	5,532,230	7/2/96	Daynes et al.			
	5,583,126	12/10/96	Daynes et al.			
	5,585,371	12/17/96	Lardy			
	5,599,806	2/4/97	Cerri et al.			
	5,641,768	6/24/97	Loria			
	5,686,438	11/11/97	Daynes et al.			
	5,696,106	12/9/97	Schwartz et al.			
	5,705,662	1/6/98	Cerri et al.			
	5,728,688	3/17/98	Labrie			
	5,763,433	6/9/98	Morfin			
	5,776,923	7/7/98	Labrie			
	5,811,418	9/22/98	Daynes et al.			
	5,824,668	10/20/98	Rubinfeld et al.			
	5,837,269	11/17/98	Daynes et al.			
	5,846,963	12/8/98	Araneo et al.			
	5,908,833	6/1/99	Brattsand et al.			
	5,912,240	6/15/99	Loria			
	5,977,095	11/2/99	Araneo et al.			
	6,013,642	1/11/00	Foulkes et al.			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.